HyBryte™ use in early-stage cutaneous T-cell lymphoma
Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma of the skin, where at later stages skin-homing malignant T-cells affect lymph nodes, blood, and visceral organs. Even though early CTCL does not affect survival, it can progress to more advanced stages of disease and have a sign...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2023-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_bdbb6ac6b01d45d1bb769e22f7ae38c8 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Brian Poligone |e author |
| 700 | 1 | 0 | |a Carolina V. Alexander-Savino |e author |
| 700 | 1 | 0 | |a Ellen J. Kim |e author |
| 700 | 1 | 0 | |a Aaron R. Mangold |e author |
| 700 | 1 | 0 | |a Jennifer Desimone |e author |
| 700 | 1 | 0 | |a Henry K. Wong |e author |
| 700 | 1 | 0 | |a Adam T. Rumage |e author |
| 700 | 1 | 0 | |a Oreola Donini |e author |
| 700 | 1 | 0 | |a Andrea Haulenbeek |e author |
| 700 | 1 | 0 | |a Christopher J. Schaber |e author |
| 700 | 1 | 0 | |a Richard Straube |e author |
| 700 | 1 | 0 | |a Christopher Pullion |e author |
| 700 | 1 | 0 | |a Alain H. Rook |e author |
| 245 | 0 | 0 | |a HyBryte™ use in early-stage cutaneous T-cell lymphoma |
| 260 | |b Frontiers Media S.A., |c 2023-11-01T00:00:00Z. | ||
| 500 | |a 2674-0338 | ||
| 500 | |a 10.3389/fddsv.2023.1298453 | ||
| 520 | |a Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma of the skin, where at later stages skin-homing malignant T-cells affect lymph nodes, blood, and visceral organs. Even though early CTCL does not affect survival, it can progress to more advanced stages of disease and have a significant effect on the quality of life of patients. Although expectant management is a treatment consideration in early disease stages, most patients cycle through different skin-directed therapies throughout their lifetime. It can become a challenge to manage the serious and accumulating risk of side effects of these therapies, including various skin cancers and skin damage. Adverse effects from topical therapies limit their long-term utility. Thus, there is an unmet need for well-characterized therapies that have a rapid onset of action and minimal long-term/cumulative side effect profile. Most recently, the results of a Phase 3 study of topical HyBryte™ as a potential treatment for CTCL demonstrated its efficacy and safety profile. This article summarizes what is known about HyBryte™, focuses on its mechanism of action, and highlights its effectiveness, safety, and tolerability in the context of other current FDA-approved topical therapies for CTCL. | ||
| 546 | |a EN | ||
| 690 | |a CTCL | ||
| 690 | |a photodynamic therapy | ||
| 690 | |a mycosis fungoides | ||
| 690 | |a cancer | ||
| 690 | |a drug discovery | ||
| 690 | |a immunology | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Drug Discovery, Vol 3 (2023) | |
| 787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fddsv.2023.1298453/full | |
| 787 | 0 | |n https://doaj.org/toc/2674-0338 | |
| 856 | 4 | 1 | |u https://doaj.org/article/bdbb6ac6b01d45d1bb769e22f7ae38c8 |z Connect to this object online. |